News

Rhinoswab Detects SARS-CoV-2 in Doherty Institute rt-PCR STudy

Rhinomed is pleased to report positive data from its lab-based spiking study of Rhinomed’s new Rhinoswab conducted at the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of The Peter Doherty Institute for Infection and Immunity (The Doherty) in Melbourne. The study’s objective was to demonstrate efficacy in detecting the SARS-CoV-2 virus at both low and … Read more

Rhinomed’s New High Comfort Nasal Swab Successfully Registered With Australian TGA

Rhinomed has successfully registered its easy to use, high load capturing, comfortable nasal swab with the Australian Therapeutic Goods Administration (TGA) as a Class 1 device. The new swab can comfortably collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and coronavirus including SARS-CoV-2. The unique … Read more

Nasal swab Registered With US FDA

Rhinomed Limited is pleased to announce that it has successfully registered its novel nasal swab with the US FDA as a Class 1 device to collect samples from the nose to detect upper respiratory tract diseases including influenza and coronavirus strains. The successful registration and conformity with the relevant standards means that Rhinomed’s novel nasal … Read more

Rhinomed Developing New Nasal Swab

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in nasal airway and respiratory technology, is advanced in developing a new high-yielding nasal swab that can collect samples from the nose to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains. Read a full copy of the report here.

Rhinomed Records Positive Year On Year Result

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, can report its FY 20 Q4 results and preliminary unaudited full year results. After a record FY20 Q3 result the company was on track to reach its full year planned targets. Confirmation during the quarter that … Read more

Rhinomed Delivers Major Milestone: Pronto to Appear in 6,336 New Stores in US

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, today announces it has received purchase orders confirming a major distribution expansion of its Pronto Clear nasal decongestion technology within one of the largest and leading pharmacy and drugstore chains in the USA. Read a full … Read more

RNO Signs 12 Year Licensing Agreement With USA’s Largest Medical Cannabis Operator

Rhinomed (ASX:RNO) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.). Read a full copy of the report here.

Appendix 4E Preliminary Final Report

Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report Read a full copy of the report here.

Business Update – June Quarter Cash Flow Report

Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k – a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17. This came off the back of another … Read more

RNO & US Based Columbia Care To Develop Nasally Delivered Dose Controlled Cannabis Based Medicines

RHINOMED & US BASED COLUMBIA CARE TO DEVELOP NASALLY DELIVERED DOSE CONTROLLED CANNABIS BASED MEDICINES June 21, 2018, ​ Melbourne, Australia. Melbourne based nasal respiratory company Rhinomed (ASX:RNO) is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC (“Columbia Care”) to license Rhinomed’s nasal platform for the delivery of medical … Read more

Mute Expands Ranging in Leading US Pharmacy

MUTE EXPANDS RANGING IN LEADING US PHARMACY – OVER 1100 NEW STORES ADDED June 19, 2018, ​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has expended its relationship with one of America’s largest pharmacy retailer – CVS. The Company has now received initial purchase orders confirming that Mute … Read more

New Retailer to Stock Mute in 3000 New USA Pharmacies

NEW RETAILER TO STOCK MUTE IN 3000 NEW USA PHARMACIES May 28 2018, ​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has entered into a new distribution agreement with, and received an initial order for stock from a new retailer. The retailer is one of America’s largest … Read more